Opzelura (ruxolitinib) has been FDA approved for eczema. Opzelura is a topical JAK inhibitor, and its indicated for short term use in patients 12 and up who have mild to moderate atopic dermatitis. It is the first topical janus kinase inhibitor approved in the United States. Currently for atopic dermatitis topical treatment, the mainstay of […]
Upadacitinib for Atopic Dermatitis (Eczema)
Upadacitinib is an oral JAK1 inhibitor being developed for patients with severe atopic dermatitis. Multiple phase 2 randomized placebo controlled studies have examined the efficacy of upadacitinib in adults and adolescent patients with moderate to severe atopic dermatitis. Published in The Lancet, 2 replicate 16-week trials showed that monotherapy with upadacitinib improved symptom and disease severity compared […]
Eczema and Dementia Risk
Past studies have suggested that there is a link between eczema and dementia. Patients with dementia have a higher prevalence of eczema than those without. According the the World Health Organization, eczema (atopic dermatitis) is 15th among all nonfatal diseases and is the largest disease burden among all skin diseases. Eczema peaks in early childhood, […]
Abrocitinib vs. Dupilumab for Atopic Dermatitis
Abrocitinib vs. Dupilumab will be an important question for many prescribing doctors with the expected FDA approval of abrocitinib soon. We have extensively discussed atopic dermatitis (eczema) in the past. For many years only topical therapies were available for this condition. Topical steroids are the mainstays of treatment, and after many years newer topical therapies […]
Baricitinib for Atopic Dermatitis (Eczema)
Baricitinib is currently being studied for the treatment of atopic dermatitis. Baricitinib is part of the family of oral Janus kinase inhibitors that are an emerging modality in the treatment of chronic allergic inflammatory disorders due to their ability to inhibit signaling of multiple pathways of cytokines. We discussed in another blog post, Abrocitinib which is […]
Omalizumab for Atopic Dermatitis
Omalizumab for atopic dermatitis has shown promising results. In JAMA Pediatrics, the researchers have demonstrated for the first time that omalizumab, which neutralizes IgE, reduced disease severity and improved quality of life in pediatric patients with severe atopic dermatitis. This was the case even in subjects with very high baseline total plasma IgE levels. Omaizumab […]
Ruxolitinib for Eczema (atopic dermatitis)
Ruxolitinib is a new medication being studied for the treat of eczema. Ruxolitinib is a selective inhibitor of Janus kinase 1 and Janus kinase 2, it potently suppresses cytokine signaling involved in atopic dermatitis pathogenesis. We discussed the Janus Kinase pathway in a previous post and how new drugs are being developed for the treatment […]
New treatments for eczema on the horizon
Eczema is an inflammatory skin disease that results in a rash and itching. This impacts a patients quality of life including depression, sleep disturbances and even suicidal ideation. Treatments include, moisturizers, topical steroids and calineurin inhibitiors. Despite treatment, many patients still suffer. Advances in recent years have brought new medications, Dupilumab and Eucrisa. Although they […]
Delgocitinib for patients with atopic dermatitis
Topical delgocitinib (JTE-052) is a novel Janus kinase inhibitor that has been shown to be effective in adults with eczema. Eczema is an itchy, inflammatory skin rash that lasts chronically and it can fluctuate. It is seen more in childhood and the majority of patients experience resolution with age. The goal of treatment is to […]
Adult Eczema a common problem
Adult eczema rates are greater than previously thought, but the frequency and characteristics of adult onset disease remain controversial. Atopic dermatitis or eczema is the leading cause of skin related disability, but most studies focus only on children. Eczema is common in adults, but it is not known whether the higher rates are from new […]